These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 26904465)
1. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives. John M; Gopinath D; Jagesh R Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465 [TBL] [Abstract][Full Text] [Related]
2. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
3. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes? Saisho Y Diseases; 2020 May; 8(2):. PubMed ID: 32403420 [TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Vivian EM Drugs Context; 2014; 3():212264. PubMed ID: 25598831 [TBL] [Abstract][Full Text] [Related]
5. Sodium/glucose cotransporter 2 inhibitors for the treatment of type 1 diabetes: what are the latest developments? Veneti S; Tziomalos K Expert Opin Pharmacother; 2021 Nov; 22(16):2261-2266. PubMed ID: 34402702 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Seufert J Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242 [TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Kurosaki E; Ogasawara H Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279 [TBL] [Abstract][Full Text] [Related]
9. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs. Chrysant SG Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076 [TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions. D'Elia JA; Segal AR; Bayliss GP; Weinrauch LA Int J Nephrol Renovasc Dis; 2017; 10():153-158. PubMed ID: 28670136 [TBL] [Abstract][Full Text] [Related]
11. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. Lee S Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644 [TBL] [Abstract][Full Text] [Related]
12. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
13. Risks Associated with SGLT2 Inhibitors: An Overview. Singh M; Kumar A Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. Liu B; Wang Y; Zhang Y; Yan B Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521 [TBL] [Abstract][Full Text] [Related]
15. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625 [TBL] [Abstract][Full Text] [Related]
16. Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes. Peene B; Benhalima K Ther Adv Endocrinol Metab; 2014 Oct; 5(5):124-36. PubMed ID: 25419452 [TBL] [Abstract][Full Text] [Related]
17. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Kim Y; Babu AR Diabetes Metab Syndr Obes; 2012; 5():313-27. PubMed ID: 22977310 [TBL] [Abstract][Full Text] [Related]
18. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin. Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592 [TBL] [Abstract][Full Text] [Related]
19. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Steen O; Goldenberg RM Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789 [TBL] [Abstract][Full Text] [Related]
20. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Lupsa BC; Inzucchi SE Diabetologia; 2018 Oct; 61(10):2118-2125. PubMed ID: 30132031 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]